Voriconazole

A triazole antifungal agent

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
10mg

￥450.00

360.00

- +
25mg

￥587.00

470.00

- +
100mg

￥987.00

790.00

- +
200mg

￥1562.00

1250.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci10400
CAS: 137234-62-9
别名: 伏立康唑,(±)-UK-109496
分子式: C16H14F3N5O
分子量: 349.31
纯度: >98%
溶解度: ≥ 34.9 mg/mL in DMSO, ≥ 45 mg/mL in EtOH with ultrasonic and warming
储存: Store at -20°C
库存: 现货

Background

Voriconazole is an inhibitor of 14α-lanosterol demethylase with IC50 value of 53nM [1].

Voriconazole is a triazole antifungal and a second-generation synthetic derivative of fluconazole. It plays its antifungal role through inhibiting cytochrome P450 (CYP 450)–dependent 14α-lanosterol demethylation, which is a vital step in the membrane ergosterol synthesis of fungi. Voriconazole has a broad antifungal spectrum. It is active against all Candida species, many Aspergillus species and other yeasts, including Cryptococcus neoformans, Trichosporon beigelii, and Saccharomyces cerevisia. Voriconazole is available in both intravenous and oral formulations. Voriconazole undergoes extensive hepatic metabolism via the cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4. In addition, voriconazole also causes some side effects, such as visual disturbances, skin rashes and elevations in hepatic enzyme levels [1, 2].

参考文献:
[1] Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000 Sep;34(9):1032-43.
[2] Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 Mar 1;36(5):630-7.

Protocol

Cell experiment [1]:
Cell lines	Aspergillus spp. and Candida spp.
Preparation method	The solubility of this compound in DMSO is >17.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Applications	Voriconazole inhibited Aspergillus spp. and Candida spp. and exhibited excellent activity against Candida spp. with MICs typically <0.125 mg/L.
Clinical trial [2]:
Patient models	Aspergillosis
Application	In the patients who received primary therapy with voriconazole, 59% had either a complete or a partial response. In the patients who received voriconazole as salvage therapy, 38% had either a complete or a partial response.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
参考文献: [1] Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000 Sep;34(9):1032-43. [2] Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 Mar 1;36(5):630-7.